Skip to main content

Table 2 Changes in protein expression of various biomarkers and their mutational status and progression free survival

From: Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib

 

Mutational status of tumor

PFS (Days)

PI3K (% change)

pPI3K (% change)

IGF1R (% change)

pMEK (% change)

cMET (% change)

pERK (% change)

pAKT (% change)

 

BRAF

385

-99.5

-97.1

-93.6

-

-72.3

-

-83.9

 

Wt

275

-46.3

-75.3

-61

-92.9

-75.8

-96.8

-90.4

 

KRAS + PIK3CA

274

-39.7

54.9

0

0

378.7

1570

2653.9

 

Wt

252

-97.7

0

-59.3

0

-86

-93.3

-61.5

 

Wt

484

-86

-86.8

-95.3

0

-97.1

-87.5

210

 

Wt

236

-63.2

-96.7

-99.4

-94.2

-73.1

-98.1

-98.7

 

Wt

109

-99.8

0

59.1

0

1261

30.6

-64.3

 

BRAF

106

483.3

97.3

1630

0

473.3

540

975

 

NRAS

106

-92.7

-96.8

-97.2

-92.5

-93.5

-99

-64.3

 

KRAS + PIK3CA

105

-99.9

0

0

0

1864.5

0

-81.8

 

KRAS

48

36020

-38.3

38.6

730

561.7

1490

2653.9

 

KRAS

47

180

770

7.6

-37.1

324.8

1.3

571

 

BRAF + KRAS

49

159.7

-96.5

12.7

-94.2

20

-81.6

-97.5

 

PIK3CA + NRAS

49

-85.7

-99.6

-99.9

-97.6

-86.4

-96.2

-81.3

*Test of null hypothesis P value

  

0.01

0.50

0.12

0.57

0.07

0.53

0.70

  1. Wt – Wild-type.
  2. Negative % change reflects downregulation; positive % change reflects upregulation.
  3. *Mann Whitney U test (2-tailed) of PFS between patient populations with upregulated or downregulated protein expression.